Table 2 Treatment and prognosis in EBLs, NEBLs and NEBLs*
Variable | EBLs (n=16) | NEBLs (n=53) | NEBLs* (n=37) | P1 | P2 |
|---|---|---|---|---|---|
Therapy in relapse | Â | Â | Â | Â | Â |
 High-dose corticosteroids pulses | 16(100%) | 53(100%) | 37(100%) | NS | NS |
 Combined with IVIG | 6(37.5%) | 17(32.0%) | 11(29.7%) | NS | NS |
 Plasmapheresis | 1(6.25%) | 1(1.89%) | 1(2.70%) | NS | NS |
Therapy in remission | Â | Â | Â | Â | Â |
 Small-dose prednisone(8–20 mg/d) | 16(100%) | 53(100%) | 37(100%) | NS | NS |
 Combined with Azathioprine(50 mg/d) | 6(37.5%) | 24(47.2%) | 19(51.4%) | NS | NS |
Prognosis | Â | Â | Â | Â | Â |
 NO. of relapse cases | 12(75%) | 39(73.5%) | 31(79.4%) | NS | NS |
 Relapse times after emergence of EBLs or symptoms relating to NMO | 1.88±0.30 | 1.23±0.14 | 1.36±0.16 | 0.04 | NS |
   NO. of spinal cord attack | 1.31±0.25 | 0.71±0.12 | 0.81 ± 0.14 | 0.021 | NS |
   NO. of optic nerves attack | 0.56±0.18 | 0.26±0.07 | 0.21 ± 0.08 | NS | 0.039 |
   NO. of Brain attack | 0.43±0.16 | 0.37±0.09 | 0.40±0.11 | NS | NS |
EDSS score | Â | Â | Â | Â | Â |
  EDSS in 6 month | 7.35± 1.48 | 4.6±1.63 | 4.62±1.64 | 0.001 | 0.001 |
  EDSS in 12 month | 7.1±1.53 | 4.15±1.64 | 4.16±1.59 | 0 | 0 |
  EDSS in 18 month | 6.88±1.49 | 3.58 ± 1.47 | 3.58 ± 1.47 | 0 | 0 |
  EDSS in 24 month | 6.70 ± 1.80 | 3.01 ± 1.36 | 3.03 ± 1.49 | 0 | 0 |
NO. of patients decreased EDSS ≥ 3 | 3(18.75%) | 18(33.96.16%) | 13(35.13%) | NS | NS |
(from onset to the last visit) |